The most notable risks include: Thyroid Tumors : Animal studies have shown that semaglutide can increase the risk of thyroid tumors, including a type called medullary thyroid carcinoma
households within an hour, says Silber
Dacha S, Mekaroonkamol P, Li L, Shahnavaz N, Sakaria S, Keilin S, et al
The semaglutide to tirzepatide conversion chart provides guidance on equivalent doses across different medications
PMID: Summary Keywords GIP/GLP-1 receptor agonist, glucagon-like peptide 1 receptor agonist, glucocorticosteroids, semaglutide, steroid-induced diabetes, steroid-induced hyperglycaemia Citation Jdrasek A, Lisowska K and Czupryniak L (2026) Evaluation of GLP-1 receptor agonist therapy in the management of steroid-induced diabetes: a narrative review
May treat lead toxicity